Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Research & Experimental (3)
- Research &;; Experimental (3)
- General & Internal (2)
- A-BETA;; MICROGLIAL ACTIVATION;; ENDOCANNABINOID SYSTEM;; TGCRND8 MICE;; TANGLES;; PROTEIN;; CANNABINOIDS;; INFLAMMATION;; BRAIN;; NEUROINFLAMMATION;; Biochemistry & Molecular Biology;; Cell Biology;; Medicine (1)
- AGGRESSIVE YOUTH TRAAY;; TREATMENT RECOMMENDATIONS;; TRENDS;; Pediatrics;; Pharmacology & Pharmacy;; Psychiatry (1)
-
- ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;; DEFICIT HYPERACTIVITY;; DISORDER;; PREFRONTAL CORTEX;; D1 GENE;; ASSOCIATION;; CHILDHOOD;; CHILDREN;; LINKAGE;; BRAIN;; DRD1;; Psychology (1)
- Activated-receptor-gamma;; health-exploratory-trials;; net-pd experience;; clinical-trial;; alzheimers-disease;; rating-scale;; futility;; neuroprotection;; progression;; validation;; Neurosciences & Neurology (1)
- Adolescence;; Diagnosis;; Premorbid;; Prodrome;; Prospective;; Psychosis;; Social adjustment;; 1ST EPISODE PSYCHOSIS;; ULTRA-HIGH-RISK;; PREMORBID ADJUSTMENT;; SCHIZOAFFECTIVE DISORDER;; NEGATIVE SYMPTOMS;; ADULT SCHIZOPHRENIA;; PRODROMAL SYMPTOMS;; BIPOLAR DISORDER;; OBSTETRIC COMPLICATIONS;; INTERRATER RELIABILITY;; Psychiatry (1)
- Adolescents;; Adverse effects;; Antipsychotics;; Children;; Pharmacovigilance;; Registry (1)
- Adolescents;; antipsychotics;; attention deficit-hyperactivity disorder;; children;; combination;; disruptive behaviour disorders;; paediatric;; polypharmacy;; 2ND-GENERATION ANTIPSYCHOTICS;; PSYCHOTROPIC MEDICATION;; ATYPICAL;; ANTIPSYCHOTICS;; PSYCHIATRIC-PATIENTS;; TARDIVE-DYSKINESIA;; CLINICAL-PRACTICE;; NATIONAL TRENDS;; ADVERSE EVENTS;; SCHIZOPHRENIA;; PATTERNS (1)
- Aggressive youth TRAAY (1)
- Aging;; cognition;; development;; diffusion tensor imaging;; executive;; functioning;; white matter;; CINGULATE CORTEX;; CORPUS-CALLOSUM;; LIFE-SPAN;; DIFFUSION;; BRAIN;; INTEGRITY;; ADOLESCENTS;; UNCERTAINTY;; CHOICE;; Neurosciences;; Psychiatry (1)
- All-cause discontinuation;; cohort study;; first-generation antipsychotics;; hospitalization;; long-acting injectable;; risperidone;; schizophrenia (1)
- Alzheimer Disease/metabolism/*physiopathology;; Brain/*metabolism/*physiopathology;; Brain Mapping;; Disease;; Female;; *Health;; Humans;; Magnetic Resonance Imaging;; Male;; Middle Aged;; Motor Activity;; Nerve Net/*physiopathology;; Parkinson Disease/metabolism/*physiopathology;; Positron-Emission Tomography;; Principal Component Analysis;; *Rest;; Task Performance and Analysis;; Pet;; default mode network;; neurodegeneration;; resting state networks (1)
- Alzheimer's disease;; antipsychotics;; psychosis;; tau;; behavioral;; disturbance;; agitation;; POSITRON-EMISSION-TOMOGRAPHY;; PLACEBO-CONTROLLED-TRIAL;; CEREBROSPINAL-FLUID TAU;; BEHAVIORAL DISTURBANCES;; NEUROPSYCHIATRIC;; SYMPTOMS;; DOUBLE-BLIND;; RISK-FACTORS;; ANTIPSYCHOTIC MEDICATIONS;; NEUROFIBRILLARY TANGLES;; ATYPICAL ANTIPSYCHOTICS;; Clinical Neurology;; Psychiatry (1)
- Anti-psychotic agent;; Aripiprazole once-monthly;; Hospitalization;; Long-acting injectable;; Schizophrenia (1)
- Antipsychotic;; pharmacogenetics;; polymorphism;; psychosis;; CLOZAPINE-INDUCED AGRANULOCYTOSIS;; DTNBP1 DYSBINDIN GENE;; INDUCED;; WEIGHT-GAIN;; HIGH-RISK HAPLOTYPE;; RECEPTOR GENE;; NEGATIVE SYMPTOMS;; DEFICIT SYNDROME;; 5-HT2A RECEPTOR;; ATYPICAL ANTIPSYCHOTICS;; FUNCTIONAL;; DISABILITY;; Psychiatry (1)
- Antipsychotics;; Quetiapine;; Aripiprazole;; Psychosis;; Schizophrenia;; Children;; Adolescents;; Randomised trial;; Benefits;; Harms;; SCHIZOPHRENIA-SPECTRUM DISORDERS;; EARLY-ONSET SCHIZOPHRENIA;; QUALITY-OF-LIFE;; FULLY CONDITIONAL SPECIFICATION;; PLACEBO-CONTROLLED;; TRIAL;; OPEN-LABEL;; 2ND-GENERATION ANTIPSYCHOTICS;; MULTIPLE IMPUTATION;; NATIONAL TRENDS;; 1ST-EPISODE SCHIZOPHRENIA;; Psychiatry (1)
- Antipsychotics;; adherence;; depot;; long-acting injection;; meta-analysis;; relapse;; schizophrenia;; treatment discontinuation;; SCHIZOAFFECTIVE DISORDER;; FLUPHENAZINE DECANOATE;; MAINTENANCE TREATMENT;; CLINICAL-TRIAL;; TERM TREATMENT;; DOUBLE-BLIND;; OPEN-LABEL;; RISPERIDONE;; THERAPY;; OLANZAPINE;; Psychiatry (1)
- Assertive community treatment;; family psychoeducation;; multifamily group;; schizophrenia;; supported education;; supported employment (1)
- Atypical antipsychotics (1)
- Autoantibodies;; behavior;; FDG-microPET;; N-methyl-D-aspartate receptor;; stereological neuron count;; RESONANCE-IMAGING FINDINGS;; GLUCOSE-METABOLISM;; MICE;; AUTOANTIBODIES;; ABNORMALITIES;; MECHANISMS;; BEHAVIOR;; IMMUNITY;; MEMORY;; PET;; Endocrinology & Metabolism;; Hematology;; Neurosciences (1)
- Autoimmune inner ear disease (AIED);; Myloperoxidase (MPO);; N-Acetylcysteine (NAC);; Tumor necrosis factor alpha (TNF-alpha) (1)
- BIPOLAR-DISORDER (1)
- Bipolar disorders;; Early recognition;; Early intervention;; Cognitive-behavioural psychotherapy;; Intervention study;; Randomised;; controlled trial;; OF-THE-LITERATURE;; ULTRA-HIGH RISK;; SPECTRUM DISORDER;; EARLY;; INTERVENTION;; RATING-SCALE;; EARLY-ONSET;; PSYCHOSIS;; THERAPY;; PREVALENCE;; PEOPLE;; Medicine (1)
- Blood flow;; dopamine;; levodopa;; metabolism;; positron emission tomography (PET) (1)
- Brain development (1)
- Brain network;; cognitive impairment;; FDG PET;; metabolic pattern;; Parkinson's disease;; frontal assessment battery;; network activity;; brain networks;; dementia;; dysfunction;; progression;; symptoms;; Endocrinology & Metabolism;; Hematology;; Neurosciences & Neurology (1)
- CD4(+) T-CELLS;; DENDRITIC CELLS;; INTERLEUKIN-1 FAMILY;; SKIN;; INFLAMMATION;; DISEASE SEVERITY;; IN-VIVO;; EXPRESSION;; TOLERANCE;; IL-36;; SUPPRESSION;; Biochemistry & Molecular Biology;; Cell Biology;; Medicine (1)
- Clinical high risk;; Prodrome;; Stress;; PERI Life Events Scale;; Daily;; Stress Inventory;; Daily hassles;; LIFE EVENTS;; PSYCHOSIS;; SCHIZOPHRENIA;; RELIABILITY;; VALIDITY;; SCALE;; ONSET;; Psychiatry (1)
Articles 31 - 60 of 66
Full-Text Articles in Medical Molecular Biology
White Matter Changes Associated With Antipsychotic Treatment In First-Episode Psychosis, P. Szeszko, D. G. Robinson, T. Ikuta, B. D. Peters, J. Gallego, J. Kane, A. K. Malhotra
White Matter Changes Associated With Antipsychotic Treatment In First-Episode Psychosis, P. Szeszko, D. G. Robinson, T. Ikuta, B. D. Peters, J. Gallego, J. Kane, A. K. Malhotra
Journal Articles
Second-generation antipsychotics are utilized extensively in the treatment of psychotic disorders and other psychiatric conditions, but the effects of these medications on human brain white matter are not well understood. We thus investigated the effects of second-generation antipsychotics on white matter integrity using tract-based spatial statistics in patients experiencing a first episode of psychosis with little or no prior antipsychotic exposure, and how potential changes were associated with metabolic side effects. Thirty-five (26 men/9 women) patients experiencing a first episode of psychosis received diffusion tensor imaging (DTI) exams, clinical assessments, and provided fasting blood samples at the onset of antipsychotic …
Prevalence And Correlates Of Antipsychotic Polypharmacy In Children And Adolescents Receiving Antipsychotic Treatment*, N. Toteja, J. Gallego, E. Saito, T. Gerhard, A. Winterstein, M. Olfson, C. U. Correll
Prevalence And Correlates Of Antipsychotic Polypharmacy In Children And Adolescents Receiving Antipsychotic Treatment*, N. Toteja, J. Gallego, E. Saito, T. Gerhard, A. Winterstein, M. Olfson, C. U. Correll
Journal Articles
Antipsychotic polypharmacy (APP), which is common in adults with psychotic disorders, is of unproven efficacy and raises safety concerns. Although youth are increasingly prescribed antipsychotics, little is known about APP in this population. We performed a systematic PubMed search (last update 26 January 2013) of studies reporting the prevalence of APP in antipsychotic-treated youth. Summary statistics and statistical tests were calculated at the study level and not weighted by sample size. Fifteen studies (n=58041, range 68-23183) reported on APP in youth [mean age=13.4 +/- 1.7 yr, 67.1 +/- 10.2% male, 77.9 +/- 27.4% treated with second-generation antipsychotics (SGAs)]. Data collected …
Aggression In Schizophrenia And Its Relationship To Neural Circuitry Of Urgency, P. Szeszko
Aggression In Schizophrenia And Its Relationship To Neural Circuitry Of Urgency, P. Szeszko
Journal Articles
No abstract provided.
Functional Development In Clinical High Risk Youth: Prediction Of Schizophrenia Versus Other Psychotic Disorders, S. I. Tarbox, J. Addington, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, D. O. Perkins, L. J. Seidman, M. T. Tsuang, E. F. Walker, S. W. Woods, +2 Additional Authors
Functional Development In Clinical High Risk Youth: Prediction Of Schizophrenia Versus Other Psychotic Disorders, S. I. Tarbox, J. Addington, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, D. O. Perkins, L. J. Seidman, M. T. Tsuang, E. F. Walker, S. W. Woods, +2 Additional Authors
Journal Articles
This study evaluates premorbid social and academic functioning in clinical high-risk individuals as predictors of transition to schizophrenia versus another psychotic disorder. Participants were 54 individuals enrolled in phase one of the North American Prodrome Longitudinal Study who over two and a half years of follow-up met criteria for schizophrenia/schizophreniform disorder (n=28) or another psychotic disorder (n=26). Social and academic functioning in childhood, early adolescence, and late adolescence was assessed at baseline using the Cannon-Spoor Premorbid Adjustment Scale. Social maladjustment in late adolescence predicted significantly higher odds of transition to schizophrenia versus another psychotic disorder independent of childhood and early …
Stress Exposure And Sensitivity In The Clinical High-Risk Syndrome: Initial Findings From The North American Prodrome Longitudinal Study (Napls), H. D. Trotman, C. W. Holtzman, E. F. Walker, J. M. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, R. K. Heinssen, T. H. Mcglashan, +5 Additional Authors
Stress Exposure And Sensitivity In The Clinical High-Risk Syndrome: Initial Findings From The North American Prodrome Longitudinal Study (Napls), H. D. Trotman, C. W. Holtzman, E. F. Walker, J. M. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, R. K. Heinssen, T. H. Mcglashan, +5 Additional Authors
Journal Articles
There is inconsistent evidence for increased stress exposure among individuals at clinical high risk (CHR) for psychosis. Yet similar to patients with a diagnosed psychotic illness, the preponderance of evidence suggests that CHR individuals tend to experience stressful life events (LE) and daily hassles (DH) as more subjectively stressful than healthy individuals. The present study utilizes data from the North American Prodrome Longitudinal Study Phase 2 (NAPLS-2) to test the hypotheses that (1) CHR individuals manifest higher self-reported stress in response to both LE and DH when compared to healthy controls (HC), (2) group differences in self-reported stress increase with …
Moderator Effects Of Working Memory On The Stability Of Adhd Symptoms By Dopamine Receptor Gene Polymorphisms During Development, J. Trampush, M. M. Jacobs, Y. L. Hurd, J. H. Newcorn, J. M. Halperin
Moderator Effects Of Working Memory On The Stability Of Adhd Symptoms By Dopamine Receptor Gene Polymorphisms During Development, J. Trampush, M. M. Jacobs, Y. L. Hurd, J. H. Newcorn, J. M. Halperin
Journal Articles
We tested the hypothesis that dopamine D1 and D2 receptor gene (DRD1 and DRD2, respectively) polymorphisms and the development of working memory skills can interact to influence symptom change over 10 years in children with attention-deficit/hyperactivity disorder (ADHD). Specifically, we examined whether improvements in working memory maintenance and manipulation from childhood to early adulthood predicted the reduction of ADHD symptoms as a function of allelic variation in DRD1 and DRD2. Participants were 76 7-11-year-old children with ADHD who were genotyped and prospectively followed for almost 10 years. ADHD symptoms were rated using the Attention Problems scale on the Child Behavior …
Antidepressants For Cognitive Impairment In Schizophrenia - A Systematic Review And Meta-Analysis, J. A. Vernon, E. Grudnikoff, A. J. Seidman, T. W. Frazier, M. S. Vemulapalli, P. Pareek, T. Goldberg, J. Kane, C. U. Correll
Antidepressants For Cognitive Impairment In Schizophrenia - A Systematic Review And Meta-Analysis, J. A. Vernon, E. Grudnikoff, A. J. Seidman, T. W. Frazier, M. S. Vemulapalli, P. Pareek, T. Goldberg, J. Kane, C. U. Correll
Journal Articles
Background: Cognitive impairment in schizophrenia is disabling, but current treatment options remain limited. Objective: To meta-analyze the efficacy and safety of adjunctive antidepressants for cognitive impairment in schizophrenia. Data sources and study selection: PubMed, MEDLINE, PsycINFO, and Cochrane Library databases were searched until 12/2013 for randomized controlled trials comparing antidepressant augmentation of antipsychotics with placebo regarding effects on cognitive functioning in schizophrenia. Data extraction: Two authors independently extracted data. Standardized mean differences (SMDs) were calculated for continuous outcomes and risk ratios for categorical outcomes. SMDs of individual cognitive tests were pooled on a study level within domains (primary outcome) and …
Rdocs Redux, D. R. Weinberger, T. Goldberg
Prospective Memory Performance In Non-Psychotic First-Degree Relatives Of Patients With Schizophrenia: A Controlled Study, F. C. Zhou, W. M. Hou, C. Y. Wang, G. S. Ungvari, H. F. K. Chiu, C. U. Correll, D. H. K. Shum, D. Man, D. T. Liu, Y. T. Xiang
Prospective Memory Performance In Non-Psychotic First-Degree Relatives Of Patients With Schizophrenia: A Controlled Study, F. C. Zhou, W. M. Hou, C. Y. Wang, G. S. Ungvari, H. F. K. Chiu, C. U. Correll, D. H. K. Shum, D. Man, D. T. Liu, Y. T. Xiang
Journal Articles
Objective: We aimed at investigating prospective memory and its socio-demographic and neurocognitive correlates in nonpsychotic, first-degree relatives (FDRs) of patients with schizophrenia compared to patients with first episode schizophrenia (FES), and healthy controls (HCs). Methods: Forty-seven FES patients, 50 non-psychotic FDRs (23 offspring and 27 siblings) of patients with chronic schizophrenia (unrelated to the FES group) and 51 HCs were studied. The Chinese version of the Cambridge Prospective Memory Test (C-CAMPROMPT) was used to measure time-based prospective memory (TBPM) and event-based prospective memory (EBPM) performance. Other cognitive functions (involving respective memory and executive functions) were evaluated with standardized tests. Results: …
Overexpressed Beta-Catenin Localizes To Plasma Membrane In Respiratory Papillomas, A. V. Lucs, A. L. Abramson, B. M. Steinberg
Overexpressed Beta-Catenin Localizes To Plasma Membrane In Respiratory Papillomas, A. V. Lucs, A. L. Abramson, B. M. Steinberg
Journal Articles
No abstract provided.
Early Efficacy Trial Of Anakinra In Corticosteroid-Resistant Autoimmune Inner Ear Disease, A. Vambutas, M. Lesser, V. Mullooly, S. Pathak, G. Zahtz, L. M. Rosen, E. Goldofsky
Early Efficacy Trial Of Anakinra In Corticosteroid-Resistant Autoimmune Inner Ear Disease, A. Vambutas, M. Lesser, V. Mullooly, S. Pathak, G. Zahtz, L. M. Rosen, E. Goldofsky
Journal Articles
BACKGROUND. Autoimmune inner ear disease (AIED) is a rare disease that results in progressive sensorineural hearing loss. Patients with AIED initially respond to corticosteroids; however, many patients become unresponsive to this treatment over time, and there is no effective alternative therapy for these individuals. METHODS. We performed a phase I/II open-label, single-arm clinical trial of the IL-1 receptor antagonist anakinra in corticosteroid-resistant AIED patients. Given that the etiology of corticosteroid resistance is likely heterogeneous, we used a Simon 2-stage design to distinguish between an unacceptable (= 30%) response rate to anakinra therapy. Subjects received 100 mg anakinra by subcutaneous injection …
Regional Brain Metabolism In A Murine Systemic Lupus Erythematosus Model, An Vo, B. T. Volpe, C. C. Tang, W. K. Schiffer, C. Kowal, P. T. Huerta, A. M. Ulug, S. L. Dewey, D. Eidelberg, B. Diamond
Regional Brain Metabolism In A Murine Systemic Lupus Erythematosus Model, An Vo, B. T. Volpe, C. C. Tang, W. K. Schiffer, C. Kowal, P. T. Huerta, A. M. Ulug, S. L. Dewey, D. Eidelberg, B. Diamond
Journal Articles
Systemic lupus erythematosus (SLE) is characterized by multiorgan inflammation, neuropsychiatric disorders (NPSLE), and antinuclear antibodies. We previously identified a subset of anti-DNA antibodies (DNRAb) cross-reactive with the N-methyl-D-aspartate receptor, present in 30% to 40% of patients, able to enhance excitatory post-synaptic potentials and trigger neuronal apoptosis. DNRAb + mice exhibit memory impairment or altered fear response, depending on whether the antibody penetrates the hippocampus or amygdala. Here, we used 18F-fluorodeoxyglucose (FDG) microPET to plot changes in brain metabolism after regional blood-brain barrier (BBB) breach. In DNRAb + mice, metabolism declined at the site of BBB breach in the first 2 …
Optimal Treatment Of Alzheimer's Disease Psychosis: Challenges And Solutions, Jeremy Koppel, Blaine Greenwald
Optimal Treatment Of Alzheimer's Disease Psychosis: Challenges And Solutions, Jeremy Koppel, Blaine Greenwald
Journal Articles
Psychotic symptoms emerging in the context of neurodegeneration as a consequence of Alzheimer's disease was recognized and documented by Alois Alzheimer himself in his description of the first reported case of the disease. Over a quarter of a century ago, in the context of attempting to develop prognostic markers of disease progression, psychosis was identified as an independent predictor of a more-rapid cognitive decline. This finding has been subsequently well replicated, rendering psychotic symptoms an important area of exploration in clinical history taking - above and beyond treatment necessity - as their presence has prognostic significance. Further, there is now …
Positive And Negative Subclinical Symptoms And Mccb Performance In Non-Psychiatric Controls, C. Korponay, G. C. Nitzburg, Anil Malhotra, P. Derosse
Positive And Negative Subclinical Symptoms And Mccb Performance In Non-Psychiatric Controls, C. Korponay, G. C. Nitzburg, Anil Malhotra, P. Derosse
Journal Articles
Considerable data support the phenomenological and temporal continuity between subclinical psychosis and psychotic disorders. In recent years, neurocognitive deficits have increasingly been recognized as a core feature of psychotic illness but there are few data seeking to elucidate the relationship between subclinical psychosis and neurocogntive deficits in non-clinical samples. The goal of the present study was to examine the relationship between subclinical positive and negative symptoms, as measured by the Community Assessment of Psychic Experiences (CAPE) and performance on the MATRICS Consensus Cognitive Battery (MCCB) in a large (n=303) and demographically diverse non-clinical sample. We found that compared to participants …
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Does A Glp-1 Receptor Agonist Change Glucose Tolerance In Patients Treated With Antipsychotic Medications? Design Of A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial, J. R. Larsen, L. Vedtofte, J. J. Holst, P. Oturai, A. Kjaer, Christoph Correll, T. Vilsboll, A. Fink-Jensen
Journal Articles
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes. Objectives To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment. Methods and analysis Trial …
Alpha 7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation By Preventing Mitochondrial Dna Release, B. Lu, K. Kwan, Y. A. Levine, P. S. Olofsson, H. Yang, J. H. Li, S. Joshi, H. C. Wang, U. Andersson, S. S. Chavan, K. J. Tracey
Alpha 7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation By Preventing Mitochondrial Dna Release, B. Lu, K. Kwan, Y. A. Levine, P. S. Olofsson, H. Yang, J. H. Li, S. Joshi, H. C. Wang, U. Andersson, S. S. Chavan, K. J. Tracey
Journal Articles
The mammalian immune system and the nervous system coevolved under the influence of cellular and environmental stress. Cellular stress is associated with changes in immunity and activation of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome, a key component of innate immunity. Here we show that alpha 7 nicotinic acetylcholine receptor (alpha 7 nAchR)-signaling inhibits inflammasome activation and prevents release of mitochondrial DNA, an NLRP3 ligand. Cholinergic receptor agonists or vagus nerve stimulation significantly inhibits inflammasome activation, whereas genetic deletion of alpha 7 nAchR significantly enhances inflammasome activation. Acetylcholine accumulates in macrophage cytoplasm after adenosine triphosphate (ATP) stimulation …
Genes And Schizophrenia: From A Festschrift Seminar Honoring William T. Carpenter Jr, Md, Anil Malhotra
Genes And Schizophrenia: From A Festschrift Seminar Honoring William T. Carpenter Jr, Md, Anil Malhotra
Journal Articles
Recent data have begun to elucidate the genetic architecture of schizophrenia, as well as provide new insights into the relationships of specific genetic factors across diagnostic boundaries, with specific symptom domains, and in the prediction of antipsychotic treatment response. Not surprisingly, work conducted at the Maryland Psychiatric Research Center (MPRC), led by Dr William Carpenter, has helped to guide the thinking behind much of this work, as well as contributed valuable data toward these efforts. In this article, I will briefly summarize some of the major findings emerging from these lines of research and highlight the role of the Dr …
The Content Of Attenuated Psychotic Symptoms In Those At Clinical High Risk For Psychosis, C. Marshall, E. Denny, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, J. Addington, +2 Additional Authors
The Content Of Attenuated Psychotic Symptoms In Those At Clinical High Risk For Psychosis, C. Marshall, E. Denny, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, J. Addington, +2 Additional Authors
Journal Articles
Recent research has started to focus on identifying individuals who are at clinical high risk of developing psychosis as a means to try and understand the predictors and mechanisms involved in the progress to a full psychotic episode. The aim of the current study was to provide an initial description and prevalence rates of specific content found within attenuated positive symptoms. The Content of Attenuated Positive Symptoms (CAPS) codebook was used by independent raters to determine the presence of content within a sample of written vignettes. Krippendorff's alpha was used to determine inter-rater reliability. Overall, the majority of items fell …
Bdnf Val66met Polymorphism And Antipsychotic-Induced Tardive Dyskinesia Occurrence And Severity: A Meta-Analysis, I. Miura, Jianping Zhang, M. Nitta, T. Lencz, John Kane, Anil Malhotra, H. Yabe, Christoph Correll
Bdnf Val66met Polymorphism And Antipsychotic-Induced Tardive Dyskinesia Occurrence And Severity: A Meta-Analysis, I. Miura, Jianping Zhang, M. Nitta, T. Lencz, John Kane, Anil Malhotra, H. Yabe, Christoph Correll
Journal Articles
Background: Tardive dyskinesia (TD) is a serious long-term consequence of antipsychotic treatment. Since brain-derived neurotrophic factor (BDNF) has potent neurotrophic activity, genetic alterations in the BDNF gene may affect antipsychotic-induced TD. Methods: Searching PubMed and Web of Science until 05/31/13, we conducted a systematic review and a meta-analysis of the effects of BDNF Val66Met polymorphism on antipsychotic-induced TD. Pooled odds ratio was calculated to assess the effects of BDNF Val66Met polymorphism on TD occurrence. Additionally, pooled standardized mean differences (Hedges'g) were calculated to assess the effects on Abnormal Involuntary Movement Scale (AIMS) total score. Results: Out of 699 potentially eligible …
Comparative Effectiveness Of Risperidone Long-Acting Injectable Vs First-Generation Antipsychotic Long-Acting Injectables In Schizophrenia: Results From A Nationwide, Retrospective Inception Cohort Study, J. Nielsen, S. O. Jensen, R. B. Friis, J. B. Valentin, Christoph Correll
Comparative Effectiveness Of Risperidone Long-Acting Injectable Vs First-Generation Antipsychotic Long-Acting Injectables In Schizophrenia: Results From A Nationwide, Retrospective Inception Cohort Study, J. Nielsen, S. O. Jensen, R. B. Friis, J. B. Valentin, Christoph Correll
Journal Articles
Objective: To compare in a generalizable sample/setting objective outcomes in patients receiving first-generation antipsychotic long-acting injectables (FGA-LAIs) or risperidone-LAI (RIS-LAI). Methods: Nationwide, retrospective inception cohort study of adults with International Classification of Diseases-10 schizophrenia using Danish registers from 1995 to 2009 comparing outcomes between clinician's/patient's choice treatment with FGA-LAIs or RIS-LAI. Primary outcome was time to psychiatric hospitalization using Cox-regression adjusting for relevant covariates. Secondary outcomes included time to all-cause discontinuation and psychiatric hospitalization in patients without LAI possession gap >28 days, and number of bed-days after psychiatric hospitalization. Results: Among 4532 patients followed for 2700 patient-years, 2078 received RIS-LAI …
Quetiapine Versus Aripiprazole In Children And Adolescents With Psychosis - Protocol For The Randomised, Blinded Clinical Tolerability And Efficacy Of Antipsychotics (Tea) Trial, A. K. Pagsberg, P. Jeppesen, D. G. Klauber, K. G. Jensen, D. Ruda, M. Stentebjerg-Olesen, P. Jantzen, S. Rasmussen, Christoph Correll, B. Fagerlund, +19 Additional Authors
Quetiapine Versus Aripiprazole In Children And Adolescents With Psychosis - Protocol For The Randomised, Blinded Clinical Tolerability And Efficacy Of Antipsychotics (Tea) Trial, A. K. Pagsberg, P. Jeppesen, D. G. Klauber, K. G. Jensen, D. Ruda, M. Stentebjerg-Olesen, P. Jantzen, S. Rasmussen, Christoph Correll, B. Fagerlund, +19 Additional Authors
Journal Articles
Background: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA) trial is to compare the benefits and harms of quetiapine versus aripiprazole in children and adolescents with psychosis in order to inform rational, effective and safe treatment selections. Methods/Design: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised, blinded clinical trial. Based on sample size estimation, 112 patients aged 12-17 years with psychosis, antipsychotic-naive or treated for a limited period are, 1:1 randomised to a 12-week, double-blind intervention …
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Antipsychotic Treatment For Children And Adolescents With Schizophrenia Spectrum Disorders: Protocol For A Network Meta-Analysis Of Randomised Trials, A. K. Pagsberg, S. Tarp, D. Glintborg, A. D. Stenstrom, A. Fink-Jensen, Christoph Correll, R. Christensen
Journal Articles
Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments …
Sentia: A Systematic Online Monitoring Registry For Children And Adolescents Treated With Antipsychotics, I. Palanca-Maresca, B. Ruiz-Antoran, G. Centeno-Soto, S. Jimenez-Fernandez, L. Garcia-Murillo, A. Siles, S. Villagra, H. Blasco-Fontecilla, L. Iruela-Cuadrado, Christoph Correll, +2 Additional Authors
Sentia: A Systematic Online Monitoring Registry For Children And Adolescents Treated With Antipsychotics, I. Palanca-Maresca, B. Ruiz-Antoran, G. Centeno-Soto, S. Jimenez-Fernandez, L. Garcia-Murillo, A. Siles, S. Villagra, H. Blasco-Fontecilla, L. Iruela-Cuadrado, Christoph Correll, +2 Additional Authors
Journal Articles
INTRODUCTION: Despite drastic increases in antipsychotic prescribing in youth, data are still limited regarding their safety in this vulnerable population, necessitating additional tools for capturing long-term, real world data. METHODS: We present SENTIA (SafEty of NeurolepTics in Infancy and Adolescence; https://SENTIA.es), an online registry created in 2010 to track antipsychotic adverse effects in Spanish youthsociodemographic, diagnostic and treatment characteristics, past personal medical/psychiatric history, healthy lifestyle habits and treatment adherence. Additionally, efficacy and adverse effect data are recorded including the Children's Global Assessment Scale; Clinical Global Impressions scale for Severity and Improvement, the Safety Monitoring Uniform Report Form, Simpson-Angus Scale, Abnormal …
Towards A Psychosis Risk Blood Diagnostic For Persons Experiencing High-Risk Symptoms: Preliminary Results From The Napls Project, D. O. Perkins, C. D. Jeffries, J. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, D. H. Mathalon, S. W. Woods, R. Heinssen, +4 Additional Authors
Towards A Psychosis Risk Blood Diagnostic For Persons Experiencing High-Risk Symptoms: Preliminary Results From The Napls Project, D. O. Perkins, C. D. Jeffries, J. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, Barbara Cornblatt, D. H. Mathalon, S. W. Woods, R. Heinssen, +4 Additional Authors
Journal Articles
INTRODUCTION: A barrier to preventative treatments for psychosis is the absence of accurate identification of persons at highest risk. A blood test that could substantially increase diagnostic accuracy would enhance development of psychosis prevention interventions. METHODS: The North American Prodrome Longitudinal Study project is a multisite endeavor that aims to better understand predictors and mechanisms for the development of psychosis. In this study, we measured expression of plasma analytes reflecting inflammation, oxidative stress, hormones, and metabolism. A "greedy algorithm" selected analytes that best distinguished persons with clinical high-risk symptoms who developed psychosis (CHR-P; n = 32) from unaffected comparison (UC) …
Brain White Matter Development Is Associated With A Human-Specific Haplotype Increasing The Synthesis Of Long Chain Fatty Acids, B. D. Peters, A. N. Voineskos, P. R. Szeszko, T. A. Lett, P. Derosse, S. Guha, K. H. Karlsgodt, M. John, T. Lencz, A. K. Malhotra, +4 Additional Authors
Brain White Matter Development Is Associated With A Human-Specific Haplotype Increasing The Synthesis Of Long Chain Fatty Acids, B. D. Peters, A. N. Voineskos, P. R. Szeszko, T. A. Lett, P. Derosse, S. Guha, K. H. Karlsgodt, M. John, T. Lencz, A. K. Malhotra, +4 Additional Authors
Journal Articles
The genetic and molecular pathways driving human brain white matter (WM) development are only beginning to be discovered. Long chain polyunsaturated fatty acids (LC-PUFAs) have been implicated in myelination in animal models and humans. The biosynthesis of LC-PUFAs is regulated by the fatty acid desaturase (FADS) genes, of which a human-specific haplotype is strongly associated with omega-3 and omega-6 LC-PUFA concentrations in blood. To investigate the relationship between LC-PUFA synthesis and human brain WM development, we examined whether this FADS haplotype is associated with age-related WM differences across the life span in healthy individuals 9-86 years of age (n = …
Early Specific Cognitive-Behavioural Psychotherapy In Subjects At High Risk For Bipolar Disorders: Study Protocol For A Randomised Controlled Trial, A. Pfennig, K. Leopold, A. Bechdolf, C. U. Correll, M. Holtmann, M. Lambert, C. Marx, T. D. Meyer, G. Juckel, M. Bauer, +5 Additional Authors
Early Specific Cognitive-Behavioural Psychotherapy In Subjects At High Risk For Bipolar Disorders: Study Protocol For A Randomised Controlled Trial, A. Pfennig, K. Leopold, A. Bechdolf, C. U. Correll, M. Holtmann, M. Lambert, C. Marx, T. D. Meyer, G. Juckel, M. Bauer, +5 Additional Authors
Journal Articles
Background: Bipolar disorders (BD) are among the most severe mental disorders with first clinical signs and symptoms frequently appearing in adolescence and early adulthood. The long latency in clinical diagnosis (and subsequent adequate treatment) adversely affects the course of disease, effectiveness of interventions and health-related quality of life, and increases the economic burden of BD. Despite uncertainties about risk constellations and symptomatology in the early stages of potentially developing BD, many adolescents and young adults seek help, and most of them suffer substantially from symptoms already leading to impairments in psychosocial functioning in school, training, at work and in their …
Child And Adolescent Psychiatrists' Attitudes And Practices Prescribing Second Generation Antipsychotics, A. M. Rodday, S. K. Parsons, C. U. Correll, A. S. Robb, B. T. Zima, T. S. Saunders, L. K. Leslie
Child And Adolescent Psychiatrists' Attitudes And Practices Prescribing Second Generation Antipsychotics, A. M. Rodday, S. K. Parsons, C. U. Correll, A. S. Robb, B. T. Zima, T. S. Saunders, L. K. Leslie
Journal Articles
Objective: The purpose of this study was to examine psychiatrists' attitudes and practices in prescribing second-generation antipsychotics (SGA) to children and adolescents (referred to here as "children") and identify factors associated with off-label SGA use. Methods: A survey was mailed to a national, randomly selected sample of 1600 child and adolescent psychiatrists identified by the American Medical Association. Multivariable logistic regression was used to identify factors, including psychiatrists' characteristics, practice characteristics, and psychiatrists' attitudes, that are associated with off-label SGA use (i.e., SGAs used in children with attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, or nonbipolar mood disorders). Results: …
Perceived Discrimination In Those At Clinical High Risk For Psychosis, M. M. Saleem, J. Stowkowy, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, S. W. Woods, +2 Additional Authors
Perceived Discrimination In Those At Clinical High Risk For Psychosis, M. M. Saleem, J. Stowkowy, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, T. H. Mcglashan, D. O. Perkins, L. J. Seidman, M. T. Tsuang, S. W. Woods, +2 Additional Authors
Journal Articles
Aim: There is evidence to suggest that perceived discrimination may be associated with psychosis. Less is known about its potential impact on those at clinical high risk (CHR) for psychosis. The aim of this study was to determine the prevalence of perceived discrimination in a CHR sample and its possible relationship to attenuated positive symptoms and negative self-beliefs. Methods: Participants were 360 CHR individuals and 180 healthy controls. Assessments included a self-report measure of perceived discrimination, the Scale of Prodromal Symptoms and the Brief Core Schema Scale. Results: CHR participants reported significantly more perceived discrimination. Perceived discrimination was significantly associated …
Age-Associated Alterations In Corpus Callosum White Matter Integrity In Bipolar Disorder Assessed Using Probabilistic Tractography, N. Toteja, P. Guvenek-Cokol, T. Ikuta, V. Kafantaris, B. D. Peters, K. E. Burdick, M. John, A. K. Malhotra, P. Szeszko
Age-Associated Alterations In Corpus Callosum White Matter Integrity In Bipolar Disorder Assessed Using Probabilistic Tractography, N. Toteja, P. Guvenek-Cokol, T. Ikuta, V. Kafantaris, B. D. Peters, K. E. Burdick, M. John, A. K. Malhotra, P. Szeszko
Journal Articles
OBJECTIVES: Atypical age-associated changes in white matter integrity may play a role in the neurobiology of bipolar disorder, but no studies have examined the major white matter tracts using nonlinear statistical modeling across a wide age range in this disorder. The goal of this study was to identify possible deviations in the typical pattern of age-associated changes in white matter integrity in patients with bipolar disorder across the age range of 9-62 years. METHODS: Diffusion tensor imaging was performed in 57 (20 male and 37 female) patients with a diagnosis of bipolar disorder and 57 (20 male and 37 female) …
Genome-Wide Mapping Of Ibd Segments In An Ashkenazi Pd Cohort Identifies Associated Haplotypes, V. Vacic, L. J. Ozelius, L. N. Clark, A. Bar-Shira, M. Gana-Weisz, T. Gurevich, A. Gusev, S. Guha, T. Lencz, A. Orr-Urtreger, +10 Additional Authors
Genome-Wide Mapping Of Ibd Segments In An Ashkenazi Pd Cohort Identifies Associated Haplotypes, V. Vacic, L. J. Ozelius, L. N. Clark, A. Bar-Shira, M. Gana-Weisz, T. Gurevich, A. Gusev, S. Guha, T. Lencz, A. Orr-Urtreger, +10 Additional Authors
Journal Articles
The recent series of large genome-wide association studies in European and Japanese cohorts established that Parkinson disease (PD) has a substantial genetic component. To further investigate the genetic landscape of PD, we performed a genome-wide scan in the largest to date Ashkenazi Jewish cohort of 1130 Parkinson patients and 2611 pooled controls. Motivated by the reduced disease allele heterogeneity and a high degree of identical-by-descent (IBD) haplotype sharing in this founder population, we conducted a haplotype association study based on mapping of shared IBD segments. We observed significant haplotype association signals at three previously implicated Parkinson loci: LRRK2 (OR = …